Acorda therapeutics to present at the canaccord genuity growth
conference
Ardsley, n.y.--(business wire)--acorda therapeutics, inc. (nasdaq:acor) today announced that michael rogers, chief financial officer, will present at the canaccord genuity growth conference in boston on wednesday, august 12 at 4:00pm. a live audio webcast of the presentation can be accessed under “investor events” in the investor section of the acorda website at www.acorda.com, or you may use the link: http://wsw.com/webcast/canaccord18/acor please log in approximately 5 minutes before the scheduled time of the presentations to ensure a timely connection. an archived version of this webcast will be available until september 12, 2015 on the investors section of www.acorda.com. about acorda therapeutics founded in 1995, acorda therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. acorda markets three fda-approved therapies, including ampyra® (dalfampridine) extended release tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (ms), as demonstrated by an increase in walking speed. the company has one of the leading pipelines in the industry of novel neurological therapies. acorda is currently developing a number of clinical and preclinical stage therapies. this pipeline addresses a range of disorders including post-stroke walking deficits, parkinson’s disease, epilepsy, neuropathic pain, heart failure, ms, and spinal cord injury. for more information, please visit the company’s website at: www.acorda.com. forward looking statements this press release includes forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. these statements are subject to risks and uncertainties that could cause actual results to differ materially, including the ability to realize the benefits anticipated from the civitas transaction and to successfully integrate civitas' operations into our operations; our ability to successfully market and sell ampyra in the u.s.; third party payers (including governmental agencies) may not reimburse for the use of ampyra or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the risk of unfavorable results from future studies of ampyra or from our other research and development programs, including cvt-301, plumiaz, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market cvt-301, plumiaz, or any other products under development; we may need to raise additional funds to finance our expanded operations and may not be able to do so on acceptable terms; the occurrence of adverse safety events with our products; delays in obtaining or failure to obtain regulatory approval of or to successfully market fampyra outside of the u.s. and our dependence on our collaboration partner biogen in connection therewith; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and, failure to comply with regulatory requirements could result in adverse action by regulatory agencies. these and other risks are described in greater detail in acorda therapeutics' filings with the securities and exchange commission. acorda may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. forward-looking statements made in this release are made only as of the date hereof, and acorda disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this release.
